A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

Completed · Phase 1

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to learn about an investigational drug known as oral lipoic acid (LA) that may help treat multiple sclerosis. This study will measure how a person's body absorbs and breaks down the drug (pharmacokinetics) and will compare four different forms of the drug from four different manufacturers as well as LA in conjunction with fish oil.

Key facts

Study ID

NCT00676156

Run by

Oregon Health and Science University

People needed

40

Starts

2005-12-01

Expected to finish

2008-11-01

Last updated by the study team

2012-11-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Definite MS by McDonald's or Poser's criteria
• EDSS ≤ 7.5
• Age 18 to 80

You may not qualify if…

• No clinically significant MS exacerbation within 30 days of the screening
• No systemically administered corticosteroids within 30 days of study entry
• Patient not pregnant or breast feeding
• No LA in previous 2 weeks
• Not on anti-coagulants such as heparin, coumadin, or aspirin during study
• No other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus) that might increase risk of patient experiencing adverse events
• Inability to give informed consent
• Any condition which would make the patient, in the opinion of the investigator, unsuitable for the study

Where it is running

• Oregon Health and Science University Multiple Sclerosis Dept. — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.